Jazz Pharmaceuticals
JAZZ
575 hedge funds and large institutions have $12.3B invested in Jazz Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 91 funds opening new positions, 227 increasing their positions, 163 reducing their positions, and 79 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 227 | Existing positions reduced: 163
24% more call options, than puts
Call options by funds: $59.1M | Put options by funds: $47.6M
17% more capital invested
Capital invested by funds: $10.5B → $12.3B (+$1.8B)
15% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 79
4.11% more ownership
Funds ownership: 101.55% → 105.66% (+4.1%)
0% more funds holding
Funds holding: 574 → 575 (+1)
13% less funds holding in top 10
Funds holding in top 10: 15 → 13 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$258M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$166M |
| 3 |
Bank of New York Mellon
New York
|
+$90.4M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$80.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$60.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$127M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$93.2M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$63.2M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$49.3M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$41.6M |
JAZZ Hedge Fund Activity: Q1 2026 in Review
575 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2026, worth a combined $12.3B — up 17% from $10.5B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new JAZZ positions and 79 closed out — a net gain of 12 holders — while 227 added to existing stakes and 163 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $258M. The largest seller was Dimensional Fund Advisors, cutting an estimated $127M.
- 575 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2026, up from 574 in Q4 2025.
- Funds reported $12.3B of Jazz Pharmaceuticals stock for Q1 2026, up 17% quarter-over-quarter.
- 91 funds opened new Jazz Pharmaceuticals positions in Q1 2026 and 79 closed out, a net change of +12 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2026 was Fidelity Investments, an estimated $258M added.
- The largest Jazz Pharmaceuticals seller in Q1 2026 was Dimensional Fund Advisors, an estimated $127M sold.
Based on aggregated 13F filings for Q1 2026.